clementia

PFIC ANNUAL INFORMATION STATEMENT
CLEMENTIA PHARMACEUTICALS INC.

This Information Statement is for the taxable year of Clementia Pharmaceuticals Inc. (the ***Corporation***) beginning on January 1, 2017 and ending on December 31, 2017 (the ***Taxable Year***) and is issued to the Corporation's Investors and their Partners.

For the Taxable Year, the Corporation:

__X__ was a passive foreign investment company ("PFIC").

___ was not a PFIC (skip earning and distribution sections).

Investor's pro-rata share of the Corporation's ordinary earnings and net capital gain (as determined under U.S. federal income tax principles) for the Taxable Year follows:

Ordinary Earnings[1]	$nil
Net Capital Gains	$nil

The amount of cash and fair market value of other property distributed or deemed distributed by the Corporation to Investor during the Taxable Year was:

Cash	$nil
Fair Market Value of Property	$nil

In accordance with Treasury Regulation Section 1.1295-1(g)(1)(iv), the Corporation will permit Investors and their direct or indirect owners to inspect and copy the Corporation's permanent books of accounts, records and other such Corporation documents as are necessary to establish that the Corporation's ordinary earnings and net capital gain, as provided in section 1293(e) of the Internal Revenue Code, are computed in accordance with U.S. income tax principles.

Date: February 27, 2018

CLEMENTIA PHARMACEUTICALS INC.

By: /s/ Michael Singer
Michael Singer, Chief Financial Officer

1. The term "ordinary earnings" means the excess of the earnings and profits of the qualified electing fund (QEF) for the taxable year over its net capital gain for the taxable year.